Richard Chesworth

6.7k total citations · 2 hit papers
32 papers, 2.4k citations indexed

About

Richard Chesworth is a scholar working on Molecular Biology, Organic Chemistry and Pharmacology. According to data from OpenAlex, Richard Chesworth has authored 32 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 5 papers in Organic Chemistry and 4 papers in Pharmacology. Recurrent topics in Richard Chesworth's work include Cancer-related gene regulation (17 papers), Epigenetics and DNA Methylation (16 papers) and Acute Myeloid Leukemia Research (3 papers). Richard Chesworth is often cited by papers focused on Cancer-related gene regulation (17 papers), Epigenetics and DNA Methylation (16 papers) and Acute Myeloid Leukemia Research (3 papers). Richard Chesworth collaborates with scholars based in United States, United Kingdom and Japan. Richard Chesworth's co-authors include Robert A. Copeland, Mikel P. Moyer, Roy M. Pollock, Margaret Porter Scott, Victoria M. Richon, Christina J. Allain, Alejandra Raimondi, Christine R. Klaus, Tim J. Wigle and Kevin W. Kuntz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Blood.

In The Last Decade

Richard Chesworth

30 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

2013 581 citations Sarah K. Knutson, Natalie M. Warholic et al. profile →
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

2013 546 citations Scott R. Daigle, Edward J. Olhava et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Chesworth United States	17	2.1k	227	223	192	191	32	2.4k
Sandra E. Wilkinson United Kingdom	20	1.6k 0.8×	287 1.3×	110 0.5×	180 0.9×	368 1.9×	34	2.7k
Jeffrey J. Hale United States	24	2.0k 1.0×	650 2.9×	174 0.8×	256 1.3×	261 1.4×	52	3.0k
Lourdes Toral‐Barza United States	28	1.9k 0.9×	514 2.3×	78 0.3×	205 1.1×	301 1.6×	41	2.6k
Deborah Card United States	17	1.6k 0.8×	275 1.2×	136 0.6×	174 0.9×	283 1.5×	21	2.3k
Xiaoshan Min United States	22	1.3k 0.6×	206 0.9×	57 0.3×	76 0.4×	199 1.0×	34	2.0k
Shawn G. Payne United States	20	2.6k 1.3×	107 0.5×	145 0.7×	213 1.1×	254 1.3×	24	2.9k
Tjeerd Barf Netherlands	19	724 0.4×	360 1.6×	165 0.7×	286 1.5×	229 1.2×	33	1.7k
Haile Tecle United States	14	1.1k 0.6×	423 1.9×	58 0.3×	168 0.9×	403 2.1×	27	1.7k
Christine Huselton United States	18	1.6k 0.8×	429 1.9×	230 1.0×	79 0.4×	162 0.8×	37	2.3k
Péter Ács United States	26	969 0.5×	70 0.3×	524 2.3×	105 0.5×	451 2.4×	42	2.1k

Countries citing papers authored by Richard Chesworth

Since Specialization

Citations

This map shows the geographic impact of Richard Chesworth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Chesworth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Chesworth more than expected).

Fields of papers citing papers by Richard Chesworth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Chesworth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Chesworth. The network helps show where Richard Chesworth may publish in the future.

Co-authorship network of co-authors of Richard Chesworth

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Chesworth. A scholar is included among the top collaborators of Richard Chesworth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Chesworth. Richard Chesworth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alford, Joshua S., John W. Lampe, Richard Chesworth, et al.. (2022). Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies. ACS Medicinal Chemistry Letters. 13(7). 1137–1143. 16 indexed citations

Morrison, Michael J., P. Ann Boriack‐Sjodin, Kerren K. Swinger, et al.. (2018). Identification of a peptide inhibitor for the histone methyltransferase WHSC1. PLoS ONE. 13(5). e0197082–e0197082. 22 indexed citations

Chan-Penebre, Elayne, Kelli Armstrong, Allison E. Drew, et al.. (2017). Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models. Molecular Cancer Therapeutics. 16(5). 850–860. 127 indexed citations

Drew, Allison E., John E. Campbell, Cuyue Tang, et al.. (2017). Abstract 5060: Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models. Cancer Research. 77(13_Supplement). 5060–5060. 3 indexed citations

Waters, Nigel J., Sherri Smith, Edward J. Olhava, et al.. (2015). Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human. Cancer Chemotherapy and Pharmacology. 77(1). 43–62. 23 indexed citations

Mitchell, Lorna H., Allison E. Drew, Scott Ribich, et al.. (2015). Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound. ACS Medicinal Chemistry Letters. 6(6). 655–659. 95 indexed citations

Campbell, John E., Kevin W. Kuntz, Sarah K. Knutson, et al.. (2015). EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. ACS Medicinal Chemistry Letters. 6(5). 491–495. 94 indexed citations

Duncan, Kenneth W., Nathalie Rioux, P. Ann Boriack‐Sjodin, et al.. (2015). Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666. ACS Medicinal Chemistry Letters. 7(2). 162–166. 103 indexed citations

Wigle, Tim J., Kerren K. Swinger, John E. Campbell, et al.. (2015). A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening. SLAS DISCOVERY. 20(6). 810–820. 31 indexed citations

10.

Rioux, Nathalie, Kenneth W. Duncan, Xiu‐Sheng Miao, et al.. (2015). Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor. Xenobiotica. 46(3). 268–277. 16 indexed citations

11.

Rioux, Nathalie, Lorna H. Mitchell, Philip R. Tiller, et al.. (2015). Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652. Drug Metabolism and Disposition. 43(7). 936–943. 5 indexed citations

12.

Rioux, Nathalie, Heike Keilhack, Blythe Thomson, et al.. (2015). Abstract A135: Physiologically-based pharmacokinetic modeling to support clinical investigation of the EZH2 inhibitor, tazemetostat (EPZ-6438) in INI1-deficient pediatric tumors. Molecular Cancer Therapeutics. 14(12_Supplement_2). A135–A135. 2 indexed citations

13.

Basavapathruni, Aravind, Edward J. Olhava, Scott R. Daigle, et al.. (2014). Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitor. Biopharmaceutics & Drug Disposition. 35(4). 237–252. 64 indexed citations

14.

Daigle, Scott R., Edward J. Olhava, Aravind Basavapathruni, et al.. (2013). Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 122(6). 1017–1025. 546 indexed citations breakdown →

15.

Basavapathruni, Aravind, Lei Jin, Scott R. Daigle, et al.. (2012). Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L. Chemical Biology & Drug Design. 80(6). 971–980. 114 indexed citations

16.

Prickaerts, Jos, Nick P. van Goethem, Richard Chesworth, et al.. (2011). EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology. 62(2). 1099–1110. 174 indexed citations

17.

Wu, Jun, V. A. Vigont, Lori Hrdlicka, et al.. (2011). Neuronal Store-Operated Calcium Entry Pathway as a Novel Therapeutic Target for Huntington's Disease Treatment. Chemistry & Biology. 18(6). 777–793. 127 indexed citations

18.

Felsenstein, Kevin M., Zhiyong Yang, Scott Nolan, et al.. (2010). P3‐295: Pharmacokinetic and pharmacodynamic analysis of the gamma‐secretase modulator (GSM) EVP‐0015962. Alzheimer s & Dementia. 6(4S_Part_17). 4 indexed citations

19.

Patzke, Holger, Richard Chesworth, Jessica Smith, et al.. (2008). Discovery and Development of Novel HDAC Inhibitors for Huntington’s Disease. Neurotherapeutics. 5(2). 371–371. 1 indexed citations

20.

Chesworth, Richard, Michael P. Zawistoski, Bruce A. Lefker, et al.. (2004). Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists. Bioorganic & Medicinal Chemistry Letters. 14(11). 2729–2733. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact